Microneedling With Minoxidil: What the Trial Showed

Microneedling earned its place in hair-loss conversations through one small, striking randomized trial: Dhurat and colleagues, International Journal of Trichology, 2013. In it, men who received weekly clinic microneedling in addition to their topical minoxidil did dramatically better over twelve weeks than men on the topical alone. That study is quoted at you — accurately and otherwise — by every roller vendor and clinic menu in the category, so this reading lays out exactly what it did, what it found, and the three ways the popular version of it overshoots.

What the trial actually did

One hundred men with mild-to-moderate androgenetic alopecia were randomized to two groups. Both used the same topical — 5% minoxidil lotion twice daily, the trial's protocol, described here as what the trial did, not as an instruction — and one group additionally received a weekly microneedling session, performed with a dermaroller at the clinic by the study team. Scalps were shaved at baseline so regrowth could be counted cleanly, hair counts were taken in a tattoo-marked 1 cm² target area, and blinded evaluators scored global photographs at week twelve.

The numbers, exactly

The gap was unusually large for this field. Mean change in hair count at twelve weeks was 91.4 with microneedling added versus 22.2 with the topical alone. On the blinded 7-point photographic scale, forty men in the microneedling group scored +2 or better; none did in the comparison group. In self-assessment, 82% of the microneedling group reported more than 50% improvement against 4.5% of the topical-only group. The authors' conclusion:

“Dermaroller along with Minoxidil treated group was statistically superior to Minoxidil treated group in promoting hair growth in men with AGA for all 3 primary efficacy measures of hair growth.” — Dhurat et al., International Journal of Trichology, 2013

The three ways the popular version overshoots

First: the trial tested an add-on, not an alternative. Every participant was on the drug; the needle's measured job was to amplify a topical, and the trial says nothing about needling instead of treatment. Second: the needling was clinic-delivered, weekly, by trained hands on shaved scalps — not a nightly bathroom habit with a $25 roller, which is a different procedure wearing the same name (our at-home derma roller safety reading covers that gap). Third: it was one 12-week, single-site, 100-man pilot — the authors called it a pilot study themselves — with hair counts in a small marked square, not years of photographs. A large effect in a small pilot is a reason for bigger trials, and a reason for hope; it is not the same thing as a settled therapy.

Why needling might help a topical work

The study's own framing is mechanism, offered as hypothesis rather than proof: microneedling is thought to stimulate the dermal papilla's growth machinery — the authors point to wound-healing growth factors and stem-cell activation — and micro-channels in the skin plausibly help a topical reach where it acts. Whatever the mechanism's final shape, the practical reading stands: in the trial, the needle amplified the drug. Nothing in that logic transfers to needling on its own, and nothing in it licenses skipping the clinician who should decide whether either belongs on your scalp.

One pilot is a lead, not a literature

The size of the effect is precisely why discipline matters in reading it. Twelve weeks is a fraction of a hair cycle; one hundred men at one centre is one clinical culture, one operator technique and one measurement setup; and striking pilot results attract publication in a way null results never do. None of that is a criticism of the investigators — they labelled the work a pilot and called for more. It is a criticism of the sales pages that flattened “promising pilot, add-on, clinic-delivered” into “microneedling quadruples minoxidil results.” When a field's most quoted number comes from its smallest denominator, the honest posture is the one the authors took: encouraged, and waiting for replication at scale.

The clinic version of the offer

Dermatology and medi-spa menus now sell scalp microneedling as courses — sometimes standalone, sometimes bundled with topicals or with PRP, typically priced per session in the low-to-mid hundreds. The trial gives you the interrogation kit: is the protocol weekly, as studied, or spaced to fit a package? Is it an add-on to prescribed treatment, as studied, or sold alone? Who holds the device — the clinician you met, or whoever is free? And what does the full course cost in writing, next to the alternatives? A clinic tracking the trial's shape has a defensible offer; one selling monthly stand-alone needling is selling past the evidence.

Where this sits in a decision

If the combination interests you, the order of operations is a dermatologist first — both parts of the combination are their territory: the drug is a medicine with its own considerations that this site deliberately does not cover, and the needling is a skin procedure with technique and hygiene stakes. Bring the trial's actual shape to that conversation: weekly, clinic-delivered, add-on, twelve weeks measured. And if a clinic quotes device-tier prices for the combination, weigh it against the other things those dollars buy — our laser cap for hair growth assessment prices the device route with the same dated-source discipline as this page.